ALTERED CALCIUM SIGNAL-TRANSDUCTION IN B-1 MALIGNANT-CELLS

Lymphocyte proliferation is guided by receptor-mediated signal transdu ction pathways that dictate the immunological response/clonality of th at cell. We have previously reported that NZB-derived malignant B-1 ce lls, which serve as a murine model for human chronic lymphocytic leuka emia, demonstrate altered expression of surface IgM and CD45 signallin g molecules, and a failure to proliferate following membrane IgM stimu lation. To examine receptor-mediated cytosolic calcium (Ca-i) signalli ng in B cell leukaemia, we studied IgM-induced Ca-i responses in malig nant B-1 cells and B cells from non-leukaemic mice. Basal Ca-i was sli ghtly lower in malignant B-1 cells than in non-leukaemic cells. Anti-I gM stimulation induced a sustained increase in Ca-i to levels 1.3-fold greater than basal Ca-i in conventional B cells. In contrast, leukaem ic B-1 cells demonstrated a sharp but transient rise in Ca-i followed by a gradual increase to levels 2.3-Fold greater than basal [Ca](i) Ca influx from extracellular sources contributed to the early and late C a-i signal in both sets of cells. Pre-incubation (2-30 min) with anti- CD45 had no effect on basal Ca-i or the anti-IgM Ca-i signal in B cell s, but reduced the Ca-i transient in malignant B-1 cells. Additional e xperiments characterized the effects of phosphorylation/dephosphorylat ion events on the Ca-i profile following anti-IgM stimulation. Protein tyrosine kinase inhibitors decreased the anti-IgM-induced Ca-i transi ent in malignant B-1 cells by 80%, but only moderately affected (40%) the Ca-i response in non-leukaemic B cells. Protein tyrosine phosphata se inhibitors and protein kinase C (PKC) activators attenuated the Ca- i response to the same degree in normal and leukaemic B cells. These r esults show that Ca-i signalling differs widely between non-malignant B cells and malignant B-1 cells, and that tyrosine phosphorylation and CD45 modulation of IgM signalling are involved in the altered Ca-i re sponses in malignant B-1 cells.